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Background
High white blood cell count at presentation is an unfavorable prognostic factor for treatment
outcome in intermediate cytogenetic risk acute myeloid leukemia. Since the impact of white
blood cell count on outcome of subgroups defined by the molecular markers NPMc+ and FLT3-
internal tandem duplication (ITD) is unknown, we addressed this issue.
Design and Methods
We studied the effect of white blood cell count on outcome in a clinically and molecularly well-
defined cohort of 525 patients with acute myeloid leukemia using these molecular markers. In
addition, since an increased white blood cell count has been associated with an increased FLT3-
ITD/FLT3 (wild-type) ratio, we investigated whether the effect of white blood cell count on
outcome could be explained by the FLT3-ITD/FLT3 ratio.  
Results
This analysis revealed that white blood cell count had no impact on outcome in patients with
the genotypic combinations ‘NPMc+without FLT3-ITD’ and ‘NPM1wild-type with or without
FLT3-ITD’. In contrast, white blood cell count had a significant impact on complete remission
rate (P=0.034), event-free survival (P=0.009) and overall survival (P<0.001) in patients with the
genotypic combination ‘NPMc+with FLT3-ITD’. A FLT3-ITD/FLT3 ratio greater than 1 was also
associated with a reduced complete remission rate (P=0.066) and significantly reduced event-
free survival (P= 0.001) and overall survival (P=0.001) in patients with the genotypic combina-
tion ‘NPMc+ with FLT3-ITD’. Multivariable analysis revealed that white blood cell count and
FLT3-ITD/FLT3 ratio were independent prognostic indicators for outcome in the subgroup with
the genotypic combination ‘NPMc+ with FLT3-ITD’.  
Conclusions
Our results demonstrate that both high white blood cell count and FLT3-ITD/FLT3 ratio are
prognostic factors in patients with acute myeloid leukemia with the genotypic combination
‘NPMc+ with FLT3-ITD'.
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Introduction
Several prognostic factors related to patients’ and dis-
ease characteristics have been described for acute
myeloid leukemia (AML).1,2 The karyotype at diagnosis is
a powerful prognostic factor for treatment outcome in
patients with AML.3-7 Various recurrent somatically
acquired molecular abnormalities have been identified
during the last years.8 Of these molecular abnormalities,
mutations in nucleophosmin (NPM1) and internal tandem
duplications of the fms-related tyrosine kinase 3 gene
(FLT3-ITD) have strong prognostic impact.
Mutations in NPM1 are the most frequently observed
molecular abnormalities, present in about 50% of AML
cases, and are associated with a favorable outcome.9-13
AML with mutated NPM1 (NPMc+) shows distinctive bio-
logical and clinical features, and is, therefore, a provision-
al entity in the World Health Organization (WHO) 2008
classification of leukemias. FLT3-ITD is another frequent
molecular abnormality and can be observed in about 20-
25% of patients with AML.14-18 Clinically, AML patients
harboring FLT3-ITD frequently have high white blood
cell (WBC) counts at presentation.14-18 The presence of
FLT3-ITD is generally considered as an unfavorable prog-
nostic factor.14-19 In particular, those cases with a FLT3-
ITD mutation/FLT3 wild-type ratio (hereafter referred to
as the FLT3-ITD/FLT3 ratio) above the median value have
a dismal prognosis.17-19 A high FLT3-ITD/FLT3 ratio points
to the absence of the FLT3 wild-type allele. 
Mutations in NPM1 and FLT3-ITD are frequently asso-
ciated. Approximately 40% of patients with NPM1muta-
tions also carry FLT3-ITD.9 Various studies have shown
that the genotypic combination ‘NPMc+ without FLT3-
ITD’ represents a subgroup with favorable prognosis.9-13
Nevertheless, the beneficial impact of NPMc+ on progno-
sis was seen in patients with as well as those without
FLT3-ITD and it appeared that both mutations in NPM1
and FLT3-ITD were significant independent predictors of
outcome.19
Besides cytogenetic and molecular abnormalities, classi-
cally, a high WBC count at presentation is considered to
be an independent prognostic factor for poor outcome in
both adults and children with AML.1,20-23 The effect of
WBC count at diagnosis is most apparent in AML with
favorable cytogenetic risk abnormalities, such as t(8;21)
and t(15;17).24-25 However, the prognostic effect of WBC
count is also present in AML patients with intermediate
cytogenetic risk abnormalities.20-23 Multivariable analysis
has shown that both WBC count and the genotypic sub-
group NPMc+ without FLT3-ITD are independent predic-
tors of outcome.11 Nevertheless, the effect of WBC count
at diagnosis on outcome of patients within the four sub-
groups defined by the molecular markers NPMc+ and
FLT3-ITD (within the intermediate cytogenetic risk
group) is unknown. 
The aim of the present survey was to investigate the
prognostic impact of WBC count at diagnosis on outcome
within AML subgroups defined by NPMc+ and FLT3-ITD
or the FLT3-ITD/FLT3 ratio. Therefore, within a clinically
and molecularly well characterized cohort of 525 patients
with de novo AML, we compared treatment outcome
among patients divided into three groups on the basis of
their WBC counts: less than 20¥109/L, 20 to 100¥109/L,
and above 100¥109/L. 
Design and Methods
Patients
The study cohort consisted of 525 consecutive adult patients
with AML who were treated according to the sequential
HOVON/SAKK AML-04, -04A, -29, -32, -42, -43 protocols (avail-
able at http://www.hovon.nl) and for whom molecular data on
NPMc+ and FLT3-ITD status were available.26-29 All patients in this
study were newly diagnosed with AML and the diagnosis was
established according to WHO criteria. Cell specimens were col-
lected at the time of diagnosis. All patients provided written
informed consent in accordance with the Declaration of Helsinki,
and the study was approved by all participating institutional
review boards. Patients were divided into cytogenetic risk groups
(favorable, intermediate, or unfavorable) in accordance with
HOVON/SAKK criteria (Table 1). Cytogenetic risk was defined as
favorable in patients with t(8;21)(q22;q22), inv(16)(p13.1;q22), or
t(16;16)(p13.1;q22) and t(15;17), and unfavorable in patients with
complex cytogenetic abnormalities (i.e. three or more distinct
clonal abnormalities), -7, -5, del 5q or del 7q, abnormalities of the
long arm of chromosome 3 (abn 3q), t(6;9)(q23;q34),
t(9;22)(q34;q11), or abnormalities of the long arm of chromosome
11 (abn 11q23). All other cytogenetic abnormalities and AML
without cytogenetic abnormalities were considered to indicate an
intermediate cytogenetic risk. The median overall survival of the
whole cohort was 16.3 months, and the median follow-up of sur-
vivors was 61.4 months. 
Guided by thresholds of WBC counts which are often clinically
used for risk stratification, the 525 patients were divided into three
groups: those with a WBC count below 20¥109/L (n=221), those
with a WBC count between 20 and 100¥109/L (n=205) and those
with a WBC above 100¥109/L (n=99). In the current
HOVON/SAKK AML study (HOVON102) the following classifi-
cations are also used; patients with t(8;21) and WBC greater than
20¥109/L are considered at intermediate risk (instead of favorable
risk) and patients with a normal karyotype (or only loss of sex
chromosomes) and a WBC greater than 100¥109/L are considered
at unfavorable risk (instead of intermediate risk).
Within our cohort 82 patients had the molecular combination
NPMc+with FLT3-ITD. Six patients of this subgroup had unclassi-
fied cytogenetics, and one patient had 5(q)/-7(q) cytogenetics.
Therefore, 75 patients with both confirmed intermediate-risk
cytogenetics and the genotypic markers NPMc+ with FLT3-ITD
were studied.
FLT3-ITD/FLT3-wildtype ratio
Amplification of the FLT3-ITD mutations was performed using
primers 11F and 11R, as described by Nakao et al.30 Ratios were
determined after agarose gel electrophoresis of the quantitative
polymerase chain reaction products.
Statistical analyses 
Statistical analyses were performed with SPSS software, release
16.0. Actuarial probabilities of overall survival (with death due to
any cause) as well as event-free survival (with failure in case of no
complete remission or relapse or death) were estimated according
to the Kaplan–Meier method. For quantitative parameters overall
differences between the cohorts were evaluated using an F-test (or
Student’s-t test in the case of two groups) for normally distributed
variables or a Kruskal-Wallis test (or Mann-Whitney-U test in the
case of two groups) for variables with a skewed distribution. For
qualitative parameters, overall group differences were evaluated
using a χ2 test. Cox regression analysis was applied to determine
the association of WBC and overall and event-free survivals with
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adjustment for possible confounding factors such as age at diagno-
sis, cytogenetic risk profile (i.e. favorable, intermediate or unfavor-
able), FLT3-ITD, NPMc+ and the transcription factor
CCAAT/enhancer binding protein α (CEBPA). All tests were two-
tailed, and a P value of less than 0.05 was considered statistically
significant.
Results
Patients
The clinicopathological, demographic, and molecular
data of the 525 patients with AML in the study cohort are
presented in Table 1. Guided by thresholds of WBC
counts which are often clinically used for risk stratifica-
tion, the 525 patients were divided into three groups:
those with a WBC count below 20¥109/L (n=221), those
with a WBC count between 20 and 100¥109/L (n=205) and
those with a WBC above 100¥109/L (n=99). The frequency
of patients with a WBC count greater than 100¥109/L
(often designated as hyperleukocytosis) appeared to be
higher in the group of AML patients with intermediate
cytogenetic risk abnormalities (21%) than in the group
with unfavorable cytogenetic risk abnormalities (9%).
Within this study cohort, 49 of 143 (34%) patients with
FLT3-ITD and 45 of 159 (28%) patients with NPMc+ pre-
sented with hyperleukocytosis (WBC >100¥109/L) at diag-
nosis. 
Impact of white blood cell count on complete 
remission rate, event-free survival and overall survival
When considering all 525 patients, hyperleukocytosis
was significantly associated with a lower complete remis-
sion rate (67% versus 84%; P<0.001), shorter event-free
survival (median 6.8 months versus 11.6 months; P=0.001)
and shorter overall survival (median 8.9 months versus 17.2
months; P=0.002) (Online Supplementary Figure S1A,B).
Furthermore, within the subgroup of patients with cyto-
genetically intermediate-risk AML, hyperleukocytosis was
H.J.M. de Jonge et al.
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Table 1. Patients’ characteristics.
Characteristics All patients WBC <20x109/L       WBC 20-100x109/L       WBC >100x109/L 
N. of patients 525 221 205 99
Median age, years (range) 47 (15-77) 46 (16-76) 48 (15-77) 46 (16-74)
Median white blood cell count ¥109/L (range) 26 (0.3-510) 5.3 (0.3-19.7) 43 (20-99.5) 135 (101.6-510)
Median blast percentage (range) 65 (1-99) 58 (1-99) 67 (2-99) 79  (3-97)
Median platelet count ¥109/L (range) 56 (3-998) 62 (3-998) 54 (5-931) 51 (13-687)
Cytogenetics
Favorable 89 (17%) 37 (17%) 38 (19%) 14 (14%)
t(8;21) 34 22 11 1
t(15;17) 20 11 8 1
inv16 35 4 19 12
Intermediate 331 (63%) 129 (58%) 133 (65%) 69 (70%)
normal karyotype 218 74 91 53
+ 8 25 13 10 2
-9q  7 3 4 0
other 81 39 28 14
Unfavorable 85 (16%) 50 (23%) 27 (13%) 8 (8%)
11q23 11 3 5 3
complex  20 13 5 2
-5(q)/-7(q) 42 29 10 3
other 12 5 7 0
Not available 20  (4%) 5 (2%) 7 (3%) 8 (8%)
Molecular genotype
NPMc+ without FLT3-ITD 77 (15%) 25 (11%) 38  (18%) 14 (14%)
NPMc+ with FLT3-ITD 82 (15%) 17 (8%) 34 (17%) 31(31%)
NPM1 wild type without FLT3-ITD 305 (58%) 164 (74%) 105 (51%) 36 (37%)
NPM1 wild type with FLT3-ITD 61 (12%) 15 (7%) 28 (14%) 18 (18%)
CEBPA wild type versusmutant$ 486/38 203/17 190/15 93/6
Allogeneic stem cell transplantation 140# 64 57 19
Autologous stem cell transplantation 68 22 33 13
Cycles to complete remission, n (%)
1 297 (57%) 126 (57%) 124 (61%) 47 (48%)
2 111 (21%) 52 (24%) 44 (21%) 15  (15%)
3 8 (2%) 3 (1%) 2 (1%) 3 (3%)
>3 5 (1%) 0 (0%) 4 (2%) 1 (1%)
no complete remission 104 (20%) 40 (18%) 31 (15%) 33 (33%)
Relapse, n (%) 202 (39%) 81 (40%) 84 (41%) 37 (37%)
Death, n (%) 316 (60%) 124 (56%) 123 (60%) 69 (70%)
NPM1: nucleophosmin 1; FLT3: fms-related tyrosine kinase 3; ITD: internal tandem duplication; NPMc+, mutated nucleophosmin 1; CEBPA, CCAAT/enhancer binding protein α;
Cytogenetic risk group classification (favorable, intermediate, and unfavorable) is described in the Design and Methods section. $CEBPA status is unknown for one patient. # indicates
12/140 patients who underwent allogeneic stem cell transplantation after non-myeloablative conditioning.
significantly associated with a lower complete remission
rate (P<0.001), shorter event-free survival (median 7.3
months versus 13.2 months; P=0.009) and shorter overall
survival (median 9.2 months versus 19.1 months; P=0.001)
(Online Supplementary Figure S1C,D). As expected, in the
subgroup of patients with favorable cytogenetic risk, a
WBC count below 20¥109/L appeared to be significantly
associated with a higher complete remission rate
(P=0.024), improved event-free survival (median 77.2
months versus 9.7 months) and improved overall survival
(median 85.5 months versus 28.9 months; P=0.001) (Online
Supplementary Figure S1E,F). Finally, in the subgroup of
patients with cytogenetically unfavorable risk AML, WBC
count did not affect the complete remission rate (P=0.593),
event-free survival (P=0.717) or overall survival (P=0.672)
(Online Supplementary Figure S1G,H).
Prognostic value of white blood cell count in the 
context of additional known risk factors for the whole
group of patients with acute myeloid leukemia
The impact of hyperleukocytosis on event-free and
overall survival in all 525 patients with AML was con-
firmed in univariate analysis. Age at diagnosis, NPMc+,
FLT3-ITD, mutated CEBPA and cytogenetic risk group (i.e.
unfavorable, intermediate and favorable risk) also correlat-
ed with event-free and overall survival (data not shown).
When we subsequently considered these variables in a
multivariable analysis, hyperleukocytosis maintained its
independent prognostic value for both event-free survival
(HR: 1.56, 95% CI: 1.16-2.11; P=0.004) and overall sur-
vival (HR: 1.67, 95% CI: 1.21-2.30; P=0.002) (Table 2).  
Prognostic value of white blood cell count in the 
context of the molecular markers NPMc+ and FLT3-ITD
within the intermediate cytogenetic risk group
The impact of WBC count on complete remission rate,
event-free survival and overall survival was evident in the
intermediate cytogenetic risk group, which contained
63% of the patients of this study cohort. Multivariate
analysis established that hyperleukocytosis, NPMc+ and
FLT3-ITD were independent predictors for event-free sur-
vival as well as overall survival (WBC count >100¥109/L:
HR: 1.39, 95% CI: 1.01-1.92, P=0.042 for event-free sur-
vival: HR: 1.59, 95% CI: 1.14-2.21, P=0.006 for overall
survival; FLT3-ITD: HR: 1.58,  95% CI: 1.18-2.13, P=0.002
for event-free survival: HR: 1.80, 95% CI: 1.32-2.45,
P<0.001 for overall survival; NPMc+: HR: 0.61,  95% CI:
0.46-0.82, P=0.001 for event-free survival: HR: 0.59, 95%
CI: 0.43-0.80, P=0.001 for overall survival). Furthermore,
there was a significant positive interaction between
NPMc+/FLT3-ITD and WBC in the multivariable model
both for event-free and overall survival (P=0.018 and
P=0.002, respectively).
Since we aimed to investigate the impact of WBC count
on outcome within the four subgroups defined by the
molecular markers NPMc+ and FLT3-ITD (within the inter-
mediate cytogenetic risk group), we subsequently focused
on these subgroups. In the most favorable genotypic sub-
group, ‘NPMc+ without FLT3-ITD’, WBC count did not
significantly affect complete remission rate (P=0.451),
event-free survival (P=0.932) or overall survival (P=0.400)
(Figure 1A,B). Furthermore, also when WBC count was
analyzed as a continuous variable, no significant associa-
tion was found between WBC count and event-free and
overall survival in the subgroup ‘NPMc+ without FLT3-
ITD’ (data not shown). Interestingly, however, in the sub-
group with the genotypic combination ‘NPMc+with FLT3-
ITD' WBC count did have a significant impact on com-
plete remission rate (P=0.034), event-free survival
(P=0.009) and overall survival (P<0.001) (Figure 1C,D).
Within this particular subgroup, it appeared that patients
with a WBC count less than 20¥109/L or between 20-
100¥109/L had  a relatively favorable prognosis with a
median overall survival of 21 and 15 months, respectively,
and estimated 5-year overall survival rates of 50% and
51%, respectively. In contrast, patients with a WBC
greater than 100¥109/L evidently had a poor prognosis
with a median overall survival of 7 months and an esti-
mated 5-year overall survival rate of 9%. So, based on
WBC count (i.e. <100 versus >100¥109/L) patients with the
genotypic combination ‘NPMc+ with FLT3-ITD’ could be
divided into two groups, one with a relatively good prog-
nosis, the other with a very poor prognosis. These results
were underscored by univariate Cox regression analyses
using WBC count as a continuous variable for event-free
survival (HR: 1.006; 95% CI: 1.002-1.010, P=0.001) and for
overall survival (HR: 1.009; 95% CI: 1.005-1.013,
Impact of WBC count  in AML
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Table 2. Multivariable analysis of WBC count as a prognostic marker
for event-free survival and overall survival in all 525 patients.
Event-free survival Overall survival
Variable HR (95% CI) P HR (95% CI) P
WBC 20-100¥109/L$ 1.09 (0.85-1.39) 0.493 1.17 (0.90-1.53) 0.233
WBC >100¥109/L¶ 1.56 (1.16-2.11) 0.004 1.67 (1.21-2.30) 0.002
Intermediate* 1.73 (1.22-2.46) 0.002 2.18 (1.46-3.26) <0.001
Poor* 3.26 (2.22-4.78) <0.001 4.06 (2.64-6.25) <0.001
Age, decades 1.08 (1.00-1.17) 0.070 1.14 (1.05-1.24) 0.003
FLT3-ITD# 1.55 (1.19-2.01) 0.001 1.72 (1.31-2.27) <0.001
NPMc+§ 0.61 (0.46-0.80) <0.001 0.58 (0.43-0.77) <0.001
CEBPAmutation^ 0.57 (0.36-0.89) 0.015 0.50 (0.30-0.83) 0.007
HR: hazard ratio; CI: confidence interval; intermediate refers to intermediate cytogenetic
risk and poor refers to poor cytogenetic risk as defined in the Design and Methods sec-
tion; WBC: white blood cell count; FLT3: fms-related tyrosine kinase 3; ITD,: internal tan-
dem duplication; NPMc+, mutated nucleophosmin 1; CEBPA, CCAAT/enhancer binding
protein α. $WBC 20-100¥109/L versusWBC <20¥109/L. ¶WBC >100¥109/L versusWBC
<20x109/L. *Cytogenetic risk versus favorable cytogenetic risk. #FLT3-ITD versus no
FLT3-ITD. §NPMc+ versus no NPMc+. ^CEBPA mutation versus no CEBPA mutation.
Table 3. WBC count and FLT3-ITD/FLT3 ratio in the 75 patients with the
genotypic combination ‘NPMC+ with FLT3-ITD’
A
White blood cell count                   FLT3    ITD / FLT3     ratio (n.)
          <1             1               >1           
<20¥109/L                                                     4                   3                       9
20-100¥109/L                                                 4                  13                     16
>100¥109/L                                                   1                  12                     13
B                                                                           
Event-free survival Overall survival
Variable HR (95% CI) P HR (95% CI) P
WBC >100¥109/L¶ 2.29 (1.30-4.03) 0.004 3.30 (1.83-5.97) <0.001
FLT3-ITD / FLT3* 2.84 (1.59-5.08) <0.001 3.19 (1.73-5.89) <0.001
Age, decades 1.13 (1.05-1.65) 0.017 1.35 (1.07-1.70) 0.011
(A) The number of patients for the three WBC groups with regards to FLT3-ITD/FLT3
ratio. FLT3 fms-related tyrosine kinase 3; ITD: internal tandem duplication. (B) HR haz-
ard ratio; CI, confidence interval, ¶WBC >100¥109/L versus WBC <100¥109/L, *FLT3
ITD/FLT3 ratio >1 versus FLT3-ITD/FLT3 ratio ≤1.
P<0.001). 
In the two other subgroups ‘NPM1 wild-type with
FLT3-ITD’ and ‘NPM1 wild-type without FLT3-ITD’,
WBC count had no evident impact on complete remission
rate, event-free survival or overall survival (Figure 1E-H).
In addition, when, analyzing WBC count as a continuous
variable, no association between WBC count and event-
free survival or overall survival was found in the sub-
groups with the genotypes ‘NPM1 wild-type with FLT3-
ITD’ and ‘NPM1 wild-type without FLT3-ITD’ (data not
shown). So, when considering the impact of WBC count
within the four subgroups defined by the molecular mark-
ers NPMc+ with FLT3-ITD, WBC count only had an impact
on outcome in patients with the genotypic combination
‘NPMc+ with FLT3-ITD’. Of note, within the subgroup of
patients with the genotypic combination ‘NPMc+ with
FLT3-ITD’ no difference in age distribution was found
between patients with a WBC count below 20¥109/L and
between 20-100¥109/L versus greater than 100¥109/L
(P=0.412): median age in years (range); 46 (24-68), 51 (18-
77) and 50 (19-68), respectively. CEBPAwas not taken into
account since only two cases had mutated CEBPA within
the subgroup of patients with the genotypic combination
‘NPMc+ with FLT3-ITD’. 
Prognostic value of FLT3-ITD/FLT3-wildtype ratio 
among patients with acute myeloid leukemia with the
genotypic combination ‘NPMc+ with FLT3-ITD’
It has been shown that the amount of FLT3 signaling is
associated with WBC count.17-19 Patients who have lost
both FLT3 alleles have higher WBC counts than patients
with both wild-type FLT3 and FLT3 -ITD alleles.17-19 We,
therefore, wondered whether the gene dosage of wild-
type FLT3 was different in patients with the genotypic
H.J.M. de Jonge et al.
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Figure 1. Impact of WBC count on event-free
survival (EFS) and overall survival (OS) in
cases with cytogenetically intermediate risk
AML defined by the molecular markers
NPMc+ and FLT3-ITD. (A) EFS according to
WBC levels in 70 cytogenetically intermedi-
ate risk AML cases with NPMc+ without FLT3-
ITD mutation. (B) OS for this group. (C) EFS
according to WBC levels in 75 cytogenetically
intermediate risk AML cases with NPMc+ and
FLT3-ITD. (D) OS for this group. (E) EFS
according to WBC levels in 40 cytogenetically
intermediate risk AML cases with wild type
NPM1 and FLT3-ITD. (F) OS for this group. (G)
EFS according to WBC levels in 146 cytoge-
netically intermediate risk AML cases with
wild-type NPM1 without FLT3-ITD. (H) OS for
this group. The P value is given for the overall
comparison across all three groups.
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combination ‘NPMc+ with FLT3-ITD’ depending on
whether they had a high or low WBC count. To address
this question, we investigated the impact of the FLT3-
ITD/FLT3 ratio on clinical outcomes within this particular
subgroup of patients. The FLT3-ITD/FLT3 ratio was
known for all 75 patients and was categorized as less than
1, 1, or more than 1. Interestingly, the FLT3-ITD/FLT3
ratio was significantly associated with event-free survival
(P=0.001) and overall survival (P=0.001) within this sub-
group of patients (Figure 2). In detail, patients with an
FLT3-ITD/FLT3 ratio greater than 1 had a significantly
shorter event-free survival (median 5.6 months versus 15.2
and 13.0 months for patients with a ratio of 1 and <1,
respectively) as well as a significantly shorter overall sur-
vival (median 7.7 months versus 16.5 and 31.3 months for
patients with a ratio of 1 and <1, respectively). Thus, it
appears that particularly patients with the genotypic com-
bination ‘NPMc+ with FLT3-ITD’ and an FLT3-ITD/FLT3
ratio greater than 1 had a poor outcome.
So far, our data indicate that the group of patients with
intermediate cytogenetic risk AML with the genotypic
combination ‘NPMc+ with FLT3-ITD’ can be further dis-
sected, with the subgroup of patients with hyperleukocy-
tosis or FLT3 ITD/FLT3 ratio greater than 1 having an
unfavorable prognosis. However, interestingly, not all
patients with hyperleukocytosis had an FLT3-ITD/FLT3
ratio greater than 1 and vice versa (Table 3A). To investi-
gate whether a FLT3-ITD/FLT3 ratio greater than 1 and
hyperleukocytosis are indeed independent prognostic fac-
tors for patients with AML with the genotypic combina-
tion ‘NPMc+ with FLT3-ITD’, a multivariable analysis was
performed. This analysis established that FLT3-ITD/FLT3
ratio greater than 1, WBC count greater than 100¥109/L
and age are independent prognostic factors. In detail, with
regards to FLT3-ITD/FLT3 ratio greater than 1, the hazard
ratio for event-free survival was 2.84 (P<001) while that
for overall survival was 3.19 (P<0.001); for hyperleukocy-
tosis the hazard ratio for event-free survival was 2.29
(P=0.004) and for overall survival 3.30 (P<0.001), and final-
ly, for age (in decades), the hazard ratio for event-free sur-
vival was 2.13 (P=0.017) and that for overall survival was
1.35 (P=0.011) (Table 3B). 
These data prompted us to propose a model in which
patients with intermediate cytogenetic risk AML with the
genotypic combination ‘NPMc+ with FLT3-ITD’ were
considered to have an unfavorable prognosis if they had a
WBC count greater than 100¥109/L or an FLT3-ITD/FLT3
ratio greater than 1. Consequently, patients with a WBC
count below 100¥109/L and an FLT3-ITD/FLT3 ratio of 1
or less were considered to have a favorable prognosis.
Within this model, patients with hyperleukocytosis or an
FLT3-ITD/FLT3 ratio greater than 1 (n=51) compared
unfavorably with patients with a WBC count below
100¥109/L and an FLT3-ITD/FLT3 ratio of 1 or less (n=24),
with regards to complete remission rate (P=0.010), event-
free survival (P<0.001) and overall survival (P<0.001)
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Figure 2. Impact of FLT3-ITD/FLT3 ratio on event-free survival (EFS)
and overall survival (OS) in cases with cytogenetically intermediate
risk AML with the genotypic combination ‘NPMc+ with FLT3-ITD’. (A)
EFS and (B) OS according to FLT3-ITD/FLT3 ratio within 75 cytoge-
netically intermediate cytogenetic risk AML cases with the genotyp-
ic combination NPMc+ with FLT3-ITD. Ratio <1: n=9; ratio 1: n=28;
ratio >1: n = 38. The P value is given for the overall comparison
across all three groups.
Figure 3. Combined effect of WBC count and FLT3-ITD/FLT3 ratio on
event-free survival (EFS) and overall survival (OS) in cases with cyto-
genetically intermediate risk AML with the genotypic combination
‘NPMc+ with FLT3-ITD’. (A) EFS in patients with WBC count
<100x109/L and FLT3-ITD/FLT3 ratio ≤1 (n=24) compared to those
with WBC count >100x109/L or FLT3-ITD/FLT3 ratio >1 (n=51) (B)
OS in these cases.
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(Figure 3). In detail, patients with a WBC count below
100¥109/L and an FLT3-ITD/FLT3 ratio of 1 or less had
median event-free and overall survivals of 24 and 33
months, and estimated 5-year event-free and overall sur-
vival rates of 71% and 79%, respectively. In contrast,
patients with hyperleukocytosis or an FLT3-ITD/FLT3
ratio greater than 1 had median event-free and overall sur-
vivals of 7 and 8 months, and estimated 5-year event-free
and overall survival rates of 16% and 18%, respectively.
Of note, the median age at diagnosis and the number of
patients who had undergone allogeneic stem cell trans-
plantation was not different between these two groups
(P=0.55 and P=0.17, respectively).
Discussion
It is generally accepted, and confirmed in this study, that
high WBC count predicts an adverse outcome among
AML patients with favorable or intermediate cytogenetic
risk.1,2,20-23 In the current study, we have focused on the
impact of WBC count at diagnosis on outcome among
patients with intermediate cytogenetic risk, divided into
subgroups according to the presence of the molecular
markers NPMc+ and FLT3-ITD. It was found that the WBC
count had an impact on complete remission rate, event-
free survival and overall survival only among the patients
with the genotypic combination ‘NPMc+ with FLT3-ITD’.
Importantly, these results were underscored when using
WBC count as a continuous variable. Apparently, the
impact of WBC count at diagnosis on treatment outcome
is dependent on the molecular genotype of AML blasts
since the poor prognostic impact of high WBC count can
be bypassed by intrinsic molecular abnormalities of the
AML blasts, such as mutated NPM1. This is consistent
with observations that NPMc+ AML blasts, independently
of FLT3-ITD, have good response to chemotherapy in vivo
and in vitro.19,31-33
Analysis of a large cohort of young adult AML patients
by the MRC study-group showed that both mutations in
NPM1 and FLT3-ITD are significant independent predic-
tors of outcome, implying that the beneficial impact of
NPMc+ on prognosis is also seen in patients with FLT3-
ITD.19 Although the prognosis of patients with AML is
better in the presence of NPMc+, various clinical studies
have shown that only patients with the genotypic combi-
nation ‘NPMc+ without FLT3-ITD’ have a favorable out-
come.9-13 Interestingly, our results show that the subgroup
of patients with AML with the genotypic combination
‘NPMc+ with FLT3-ITD’ can be further divided into sub-
groups with favorable and unfavorable prognosis based on
WBC count and FLT3-ITD/FLT3 ratio. It seems that the
less favorable clinical course of patients with NPMc+ AML,
imposed by the presence of FLT3-ITD, does not apply for
those patients with WBC counts below 100¥109/L and an
FLT3-ITD/FLT3 ratio greater than 1. Indeed, the prognosis
of patients with the genotypic combination ‘NPMc+ with
FLT3-ITD’ and lower WBC counts and FLT3-ITD/FLT3
ratio greater than 1 appeared comparable to that of
patients with the genotypic combination ‘NPMc+ without
FLT3-ITD’.  
A number of studies suggested that patients with AML
harboring FLT3-ITD have a worse outcome than patients
without FLT3-ITD.14-18 However, the number of mutated
alleles, rather than its presence or the insertion site of the
ITD, has been shown to affect outcome.17-19,34,35 Likewise,
in our study we also found that patients with the genotyp-
ic combination ‘NPMc+ with FLT3-ITD’ and high levels of
the mutant allele (i.e. an FLT3-ITD/FLT3 ratio >1) had sig-
nificantly worse long-term outcome. It is likely that higher
levels of FLT3-ITD might trigger pathways involved in
chemoresistance more intensively, for example by
enhancing DNA repair and salvage of damaged cells.36 Our
observations confirm the importance of the FLT3-
ITD/FLT3 ratio, representing the FLT3-ITD allelic burden,
with regards to prognosis and demonstrate that WBC
count is not a surrogate marker for the FLT3-ITD/FLT3
ratio, but indeed is an independent prognostic factor.  
The importance of the WBC count and FLT3-ITD/FLT3
ratio as prognostic factors in AML patients with the geno-
typic combination ‘NPMc+ with FLT3-ITD’ needs to be
confirmed in further cohorts of patients. However, for the
future it will be of interest to study whether patients with
the genotypic combination ‘NPMc+ with FLT3-ITD’ and
low WBC count and an FLT3-ITD/FLT3 ratio less than 1
can be excluded from consolidation therapy with allo-
geneic hematopoietic cell transplantation. This would
extend the work of Schlenk et al.,13 who demonstrated that
patients with cytogenetically normal karyotype AML
bearing the genotypic combination ‘NPMc+without FLT3-
ITD’ had no survival benefit from allogeneic hematopoiet-
ic cell transplantation, with an overall survival of 50-60%. 
In conclusion, the present study demonstrates that high
WBC count and FLT3-ITD/FLT3 ratio are important prog-
nostic factors in patients with AML with the genotypic
combination ‘NPMc+ with FLT3-ITD'.
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